Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era

被引：8
|
作者：
Hanzawa, Kyoko [1 ]
Momose, Shuji [2 ,3 ]
Higashi, Morihiro [2 ]
Tokuhira, Michihide [1 ]
Watanabe, Reiko [1 ]
Kajino, Kazunori [3 ]
Hino, Okio [3 ]
Itoyama, Shinji [2 ]
Kizaki, Masahiro [1 ]
Tamaru, Jun-Ichi [2 ]
机构：
[1] Saitama Med Univ, Dept Hematol, Saitama Med Ctr, Saitama, Japan
[2] Saitama Med Univ, Dept Pathol, Saitama Med Ctr, Saitama, Japan
[3] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan
来源：
LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 11期
关键词：
YB-1; diffuse large B-cell lymphoma; rituximab; P-glycoprotein; P-GLYCOPROTEIN EXPRESSION; HUMAN BREAST CANCERS; NUCLEAR EXPRESSION; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; R-CHOP; YB-1; CHEMOTHERAPY; DISEASE; LOCALIZATION;
D O I：
10.3109/10428194.2010.522285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The expression of YB-1 has been reported to predict poor clinical outcome in many human malignancies, including hematopoietic malignancies. In this study, we investigated the correlations between YB-1 expression and the clinicopathological features of patients with diffuse large B-cell lymphoma (DLBCL) in a single institution. The expression of YB-1 was analyzed in 168 cases by immunohistochemistry. Fifteen out of 168 cases (8.9%) showed cytoplasmic expression of YB-1. The expression of YB-1 was significantly associated with 5-year overall survival (OS) (p = 0.023). Rituximab plus CHOP therapy (n = 94) improved the 5-year survival rate in both YB-1-positive and -negative patients. In conclusion, the data presented in this report provide evidence that the cytoplasmic expression of YB-1 is a poor prognosis factor in DLBCL treated with CHOP therapy, whereas rituximab improves the survival of both YB-1-positive and -negative patients with DLBCL.
引用
收藏
页码：2054 / 2062
页数：9
相关论文
共 50 条
  • [11] Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht, Christian
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2012, : 410 - 416
  • [12] Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era
    Mounier, Nicolas
    Gisselbrecht, Christian
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) : 209 - 213
  • [13] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
    Barrans, Sharon
    Crouch, Simon
    Smith, Alex
    Turner, Kathryn
    Owen, Roger
    Patmore, Russell
    Roman, Eve
    Jack, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3360 - 3365
  • [14] The Expression Level and Prognostic Value of Y-Box Binding Protein-1 in Rectal Cancer
    Zhang, Yu
    Zhao, Ping-Wu
    Feng, Gang
    Xie, Gang
    Wang, An-Qun
    Yang, Yong-Hong
    Wang, Dong
    Du, Xiao-Bo
    PLOS ONE, 2015, 10 (03):
  • [15] Prognostic impact of bone marrow involvement for patients with diffuse large B-cell lymphoma in the era of rituximab
    Kang, B. W.
    Lee, Y. J.
    Chae, Y. S.
    Moon, J. H.
    Kim, J. G.
    Sohn, S. K.
    Suh, J. S.
    Park, T. I.
    Kim, M. K.
    Hyun, M. S.
    Kim, H. J.
    Lee, J.
    Yang, D. H.
    Bae, S. H.
    Ryoo, H.
    Kwon, K. Y.
    Kim, J. Y.
    Do, Y. R.
    Park, K. U.
    Kim, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [17] The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma
    Yasen, M
    Kajino, K
    Kano, S
    Tobita, H
    Yamamoto, J
    Uchiumi, T
    Kon, S
    Maeda, M
    Obulhasim, G
    Arii, S
    Hino, O
    CLINICAL CANCER RESEARCH, 2005, 11 (20) : 7354 - 7361
  • [18] Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era
    Flowers, Christopher R.
    Cohen, Jonathon B.
    Khan, Mohammad K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 557 - 558
  • [19] A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
    Hosein, Peter J.
    Maragulia, Jocelyn C.
    Salzberg, Matthew P.
    Press, Oliver W.
    Habermann, Thomas M.
    Vose, Julie M.
    Bast, Martin
    Advani, Ranjana H.
    Tibshirani, Robert
    Evens, Andrew M.
    Islam, Nahida
    Leonard, John P.
    Martin, Peter
    Zelenetz, Andrew D.
    Lossos, Izidore S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 358 - 363
  • [20] The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
    T Kobayashi
    J Kuroda
    I Yokota
    K Tanba
    T Fujino
    S Kuwahara
    R Isa
    J Yamaguchi
    E Kawata
    T Akaogi
    H Uchiyama
    H Kaneko
    N Uoshima
    Y Kobayashi
    S Teramukai
    M Taniwaki
    Blood Cancer Journal, 2016, 6 : e383 - e383
12345